The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
BRAF, PIK3CA, and PTEN status and benefit from cetuximab (CET) in the treatment of advanced colorectal cancer (CRC): Results from NCIC CTG/AGITG CO.17.
Derek J. Jonker
No relevant relationships to disclose
Christos Stelios Karapetis
Consultant or Advisory Role - Merck Serono
Christopher J. O'Callaghan
No relevant relationships to disclose
Celia Marginean
No relevant relationships to disclose
John Raymond Zalcberg
Consultant or Advisory Role - Merck Serono
Research Funding - Bristol-Myers Squibb; Merck Serono
Other Remuneration - Merck Serono
John Simes
Research Funding - Bristol-Myers Squibb
Malcolm J. Moore
No relevant relationships to disclose
Niall Christopher Tebbutt
Consultant or Advisory Role - Merck Serono (U)
Timothy Jay Price
Consultant or Advisory Role - Merck Serono (U)
Manijeh Daneshmand
No relevant relationships to disclose
Jennifer Hanson
No relevant relationships to disclose
Jeremy David Shapiro
Consultant or Advisory Role - Merck Serono
Nick Pavlakis
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono
Peter Gibbs
No relevant relationships to disclose
Guy A. Van Hazel
No relevant relationships to disclose
Ursula Joan Yu Min Lee
No relevant relationships to disclose
Rashida Haq
No relevant relationships to disclose
Shakeel Virk
No relevant relationships to disclose
Dongsheng Tu
No relevant relationships to disclose
Ian Lorimer
No relevant relationships to disclose